Beremagene Geperpavec

戈合贝基

Report date: 2025/07/28 16:54:11

Base Information

Drug NameBeremagene Geperpavec
Drug Alias NameB-VecBercolagene telserpavecberemagene geperpavec-svdtB-VECVyjuvek +[9] 
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Herpes simplex virus vector > HSV-1 vector
Mechanisms of ActionCOL7A1 gene transference
TargetsCollagen alpha-1(VII) chain
Therapy Area/IndicationsEpidermolysis Bullosa DystrophicaCarcinoma, Squamous Cell
Global Approved IndicationsEpidermolysis Bullosa Dystrophica
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2023/05/19
Country/TerritoryUnited StatesItalyEU +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesKrystal Biotech Inc
China Registration ClassN/A

Develop Information

Active CompaniesKrystal Biotech IncStanford University
Inactive CompaniesN/A
Active IndicationsEpidermolysis Bullosa DystrophicaCarcinoma, Squamous Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG